{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:24:44Z","timestamp":1790281484927,"version":"4.1.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10072-021-05237-8","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T05:59:01Z","timestamp":1618466341000},"page":"2673-2682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0031-6916","authenticated-orcid":false,"given":"Giacomo","family":"Grassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Albani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Terenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Razzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ramat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"issue":"5","key":"5237_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67(5):589\u2013595. https:\/\/doi.org\/10.1001\/archneurol.2010.65","journal-title":"Arch Neurol"},{"issue":"3","key":"5237_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S1474-4422(17)30004-2","volume":"16","author":"V Voon","year":"2017","unstructured":"Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, Obeso J, Bezard E, Fernagut PO (2017) Impulse control disorders and levodopa-induced dyskinesias in Parkinson\u2019s disease: an update. Lancet Neurol 16(3):238\u2013250. https:\/\/doi.org\/10.1016\/S1474-4422(17)30004-2","journal-title":"Lancet Neurol"},{"key":"5237_CR3","doi-asserted-by":"publisher","first-page":"4925015","DOI":"10.1155\/2019\/4925015","volume":"3","author":"M Kov\u00e1cs","year":"2019","unstructured":"Kov\u00e1cs M, Makkos A, Pint\u00e9r D, Juh\u00e1sz A, Darnai G, Kar\u00e1di K, Janszky J, Kov\u00e1cs N (2019) Screening for problematic internet use may help identify impulse control disorders in Parkinson\u2019s disease. Behav Neurol 3:4925015. https:\/\/doi.org\/10.1155\/2019\/4925015","journal-title":"Behav Neurol"},{"issue":"3","key":"5237_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.parkreldis.2009.12.002","volume":"16","author":"JY Lee","year":"2010","unstructured":"Lee JY, Kim JM, Kim JW, Cho J, Lee WY, Kim HJ, Jeon BS (2010) Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 16(3):202\u2013207. https:\/\/doi.org\/10.1016\/j.parkreldis.2009.12.002","journal-title":"Parkinsonism Relat Disord"},{"key":"5237_CR5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders: diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Arlington","edition":"5"},{"key":"5237_CR6","unstructured":"International Statistical Classification of Diseases and Related Health Problems (11th ed; ICD-11; World Health Organization, 2020)"},{"issue":"3","key":"5237_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.chc.2016.03.004","volume":"25","author":"AG Jorgenson","year":"2016","unstructured":"Jorgenson AG, Hsiao RC, Yen CF (2016) Internet addiction and other behavioral addictions. Child Adolesc Psychiatr Clin N Am 25(3):509\u2013520. https:\/\/doi.org\/10.1016\/j.chc.2016.03.004","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"5237_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/bs.irn.2017.04.006","volume":"133","author":"D Weintraub","year":"2017","unstructured":"Weintraub D, Claassen DO (2017) Impulse control and related disorders in Parkinson\u2019s disease. Int Rev Neurobiol 133:679\u2013717. https:\/\/doi.org\/10.1016\/bs.irn.2017.04.006","journal-title":"Int Rev Neurobiol"},{"issue":"5","key":"5237_CR9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.parkreldis.2014.01.019","volume":"20","author":"K Wu","year":"2014","unstructured":"Wu K, Politis M, O\u2019Sullivan SS, Lawrence AD, Warsi S, Lees A, Piccini P (2014) Problematic Internet use in Parkinson\u2019s disease. Parkinsonism Relat Disord 20(5):482\u2013487. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.01.019","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"5237_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","volume":"68","author":"G Giovannoni","year":"2000","unstructured":"Giovannoni G, O\u2019Sullivan JD, Turner K, Manson AJ, Lees AJ (2000) Hedonistic homeostatic dysregulation in patients with Parkinson\u2019s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68(4):423\u2013428. https:\/\/doi.org\/10.1136\/jnnp.68.4.423","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"5237_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/mdc3.12671","volume":"5","author":"P Barbosa","year":"2018","unstructured":"Barbosa P, Djamshidian A, Lees AJ, Warner TT (2018) The outcome of dopamine dysregulation syndrome in Parkinson\u2019s disease: a retrospective postmortem study. Mov Disord Clin Pract 5(5):519\u2013522. https:\/\/doi.org\/10.1002\/mdc3.12671","journal-title":"Mov Disord Clin Pract"},{"issue":"12","key":"5237_CR12","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/jnnp-2017-315985","volume":"88","author":"N Warren","year":"2017","unstructured":"Warren N, O\u2019Gorman C, Lehn A, Siskind D (2017) Dopamine dysregulation syndrome in Parkinson\u2019s disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry 88(12):1060\u20131064. https:\/\/doi.org\/10.1136\/jnnp-2017-315985","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"5237_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/mds.23508","volume":"26","author":"AH Spencer","year":"2011","unstructured":"Spencer AH, Rickards H, Fasano A, Cavanna AE (2011) The prevalence and clinical characteristics of punding in Parkinson\u2019s disease. Mov Disord 26(4):578\u2013586. https:\/\/doi.org\/10.1002\/mds.23508","journal-title":"Mov Disord"},{"issue":"21","key":"5237_CR14","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMcp1313051","volume":"370","author":"D Mataix-Cols","year":"2014","unstructured":"Mataix-Cols D (2014) Clinical practice. Hoarding disorder. N Engl J Med 370(21):2023\u20132030. https:\/\/doi.org\/10.1056\/NEJMcp1313051","journal-title":"N Engl J Med"},{"issue":"6","key":"5237_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1192\/bjp.bp.113.130195","volume":"203","author":"AE Nordsletten","year":"2013","unstructured":"Nordsletten AE, Reichenberg A, Hatch SL, Fern\u00e1ndez de la Cruz L, Pertusa A, Hotopf M, Mataix-Cols D (2013) Epidemiology of hoarding disorder. Br J Psychiatry 203(6):445\u2013452. https:\/\/doi.org\/10.1192\/bjp.bp.113.130195","journal-title":"Br J Psychiatry"},{"issue":"2","key":"5237_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jagp.2019.08.022","volume":"28","author":"MR Lo Monaco","year":"2020","unstructured":"Lo Monaco MR, Di Stasio E, Zuccal\u00e0 G, Petracca M, Genovese D, Fusco D, Silveri MC, Liperoti R, Ricciardi D, Cipriani MC, Laudisio A, Bentivoglio AR (2020) Prevalence of obsessive-compulsive symptoms in elderly Parkinson disease patients: a case-control study. Am J Geriatr Psychiatry 28(2):167\u2013175. https:\/\/doi.org\/10.1016\/j.jagp.2019.08.022","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"5237_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.addbeh.2013.11.005","volume":"39","author":"L Gaboriau","year":"2014","unstructured":"Gaboriau L, Victorri-Vigneau C, G\u00e9rardin M, Allain-Veyrac G, Jolliet-Evin P, Grall-Bronnec M (2014) Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. Addict Behav 39(3):562\u2013565. https:\/\/doi.org\/10.1016\/j.addbeh.2013.11.005","journal-title":"Addict Behav"},{"issue":"3","key":"5237_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/mds.25291","volume":"28","author":"J Bastiaens","year":"2013","unstructured":"Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ (2013) Prospective cohort study of impulse control disorders in Parkinson\u2019s disease. Mov Disord 28(3):327\u2013333. https:\/\/doi.org\/10.1002\/mds.25291","journal-title":"Mov Disord"},{"issue":"2","key":"5237_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/mds.24023","volume":"27","author":"D Weintraub","year":"2012","unstructured":"Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A (2012) Questionnaire for Impulsive-Compulsive Disorders in Parkinson\u2019s Disease-Rating Scale. Mov Disord 27(2):242\u2013247. https:\/\/doi.org\/10.1002\/mds.24023","journal-title":"Mov Disord"},{"issue":"4","key":"5237_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1586\/14737175.2016.1158103","volume":"16","author":"A Ramirez-Zamora","year":"2016","unstructured":"Ramirez-Zamora A, Gee L, Boyd J, Biller J (2016) Treatment of impulse control disorders in Parkinson\u2019s disease: practical considerations and future directions. Expert Rev Neurother 16(4):389\u2013399. https:\/\/doi.org\/10.1586\/14737175.2016.1158103","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"5237_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/WNF.0b013e31826e6e6d","volume":"35","author":"S Perez-Lloret","year":"2012","unstructured":"Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, Montastruc JL, Rascol O (2012) Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol 35(6):261\u2013265. https:\/\/doi.org\/10.1097\/WNF.0b013e31826e6e6d","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"5237_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1590\/0004-282X20180052","volume":"76","author":"AP Vargas","year":"2018","unstructured":"Vargas AP, Cardoso FEC (2018) Impulse control and related disorders in Parkinson\u2019s disease. Arq Neuropsiquiatr 76(6):399\u2013410. https:\/\/doi.org\/10.1590\/0004-282X20180052","journal-title":"Arq Neuropsiquiatr"},{"key":"5237_CR23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1146\/annurev-clinpsy-032813-153705","volume":"10","author":"BB Averbeck","year":"2014","unstructured":"Averbeck BB, O\u2019Sullivan SS, Djamshidian A (2014) Impulsive and compulsive behaviors in Parkinson\u2019s disease. Annu Rev Clin Psychol 10:553\u2013580. https:\/\/doi.org\/10.1146\/annurev-clinpsy-032813-153705","journal-title":"Annu Rev Clin Psychol"},{"issue":"2","key":"5237_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/00023210-200923020-00005","volume":"23","author":"SS O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan SS, Evans AH, Lees AJ (2009) Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 23(2):157\u2013170. https:\/\/doi.org\/10.2165\/00023210-200923020-00005","journal-title":"CNS Drugs"},{"issue":"3","key":"5237_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/mdc3.12416","volume":"4","author":"P Barbosa","year":"2016","unstructured":"Barbosa P, Lees AJ, Magee C, Djamshidian A, Warner TT (2016) A retrospective evaluation of the frequency of impulsive compulsive behaviors in Parkinson\u2019s disease patients treated with continuous waking day apomorphine pumps. Mov Disord Clin Pract 4(3):323\u2013328. https:\/\/doi.org\/10.1002\/mdc3.12416","journal-title":"Mov Disord Clin Pract"},{"issue":"3","key":"5237_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jnnp-2012-303988","volume":"85","author":"R Cilia","year":"2014","unstructured":"Cilia R, Siri C, Canesi M, Zecchinelli AL, De Gaspari D, Natuzzi F, Tesei S, Meucci N, Mariani CB, Sacilotto G, Zini M, Ruffmann C, Pezzoli G (2014) Dopamine dysregulation syndrome in Parkinson\u2019s disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry 85(3):311\u2013318. https:\/\/doi.org\/10.1136\/jnnp-2012-303988","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"5237_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/archneurol.2009.294","volume":"67","author":"CA Rabinak","year":"2010","unstructured":"Rabinak CA, Nirenberg MJ (2010) Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 67(1):58\u201363. https:\/\/doi.org\/10.1001\/archneurol.2009.294","journal-title":"Arch Neurol"},{"issue":"1-2","key":"5237_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jns.2011.07.012","volume":"310","author":"R Katzenschlager","year":"2011","unstructured":"Katzenschlager R (2011) Dopaminergic dysregulation syndrome in Parkinson\u2019s disease. J Neurol Sci 310(1-2):271\u2013275. https:\/\/doi.org\/10.1016\/j.jns.2011.07.012","journal-title":"J Neurol Sci"},{"issue":"2","key":"5237_CR29","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1124\/jpet.102.039867","volume":"303","author":"MJ Millan","year":"2002","unstructured":"Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303(2):791\u2013804. https:\/\/doi.org\/10.1124\/jpet.102.039867","journal-title":"J Pharmacol Exp Ther"},{"key":"5237_CR30","first-page":"144","volume":"27","author":"B Magennis","year":"2012","unstructured":"Magennis B, Cashell A, O\u2019Brien D, Lynch T (2012) An audit of apomorphine in the management of complex idiopathic Parkinson\u2019s disease in Ireland. Mov Disord 27:144","journal-title":"Mov Disord"},{"issue":"4","key":"5237_CR31","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.26067","volume":"30","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, Henriksen T, Martin A, Calandrella D, Rizos A, Bryndum N, Glad A, Dafsari HS, Timmermann L, Ebersbach G, Kramberger MG, Samuel M, Wenzel K, Tomantschger V, Storch A, Reichmann H, Pirtosek Z, Trost M, Svenningsson P, Palhagen S, Volkmann J, Chaudhuri KR (2015) EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease. Mov Disord 30(4):510\u2013516. https:\/\/doi.org\/10.1002\/mds.26067","journal-title":"Mov Disord"},{"issue":"4","key":"5237_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/WNF.0000000000000091","volume":"38","author":"A Todorova","year":"2015","unstructured":"Todorova A, Samuel M, Brown RG, Chaudhuri KR (2015) Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 years\u2019 follow-up. Clin Neuropharmacol 38(4):132\u2013134. https:\/\/doi.org\/10.1097\/WNF.0000000000000091","journal-title":"Clin Neuropharmacol"},{"issue":"14","key":"5237_CR33","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/mds.25636","volume":"28","author":"MJ Catal\u00e1n","year":"2013","unstructured":"Catal\u00e1n MJ, de Pablo-Fern\u00e1ndez E, Villanueva C, Fern\u00e1ndez-Diez S, Lape\u00f1a-Montero T, Garc\u00eda-Ramos R, L\u00f3pez-Vald\u00e9s E (2013) Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson\u2019s disease. Mov Disord 28(14):2007\u20132010. https:\/\/doi.org\/10.1002\/mds.25636","journal-title":"Mov Disord"},{"issue":"5","key":"5237_CR34","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/JCP.0000000000000762","volume":"37","author":"FJ Jim\u00e9nez-Jim\u00e9nez","year":"2017","unstructured":"Jim\u00e9nez-Jim\u00e9nez FJ, Alonso-Navarro H, Valle-Arcos D (2017) Hypersexuality possibly associated with safinamide. J Clin Psychopharmacol 37(5):635\u2013636. https:\/\/doi.org\/10.1097\/JCP.0000000000000762","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"5237_CR35","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/WNL.0000000000000729","volume":"83","author":"K Papay","year":"2014","unstructured":"Papay K, Xie SX, Stern M, Hurtig H, Siderowf A, Duda JE, Minger J, Weintraub D (2014) Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 83(9):826\u2013833. https:\/\/doi.org\/10.1212\/WNL.0000000000000729","journal-title":"Neurology"},{"issue":"4","key":"5237_CR36","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/gps.5255","volume":"35","author":"AJ Petkus","year":"2020","unstructured":"Petkus AJ, Filoteo JV, Schiehser DM, Gomez ME, Hui JS, Jarrahi B, McEwen S, Jakowec MW, Petzinger GM (2020) Mild cognitive impairment, psychiatric symptoms, and executive functioning in patients with Parkinson\u2019s disease. Int J Geriatr Psychiatry 35(4):396\u2013404. https:\/\/doi.org\/10.1002\/gps.5255","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"5237_CR37","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/mds.23567","volume":"26","author":"C Vitale","year":"2011","unstructured":"Vitale C, Santangelo G, Trojano L, Verde F, Rocco M, Grossi D, Barone P (2011) Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson\u2019s disease. Mov Disord 26(5):830\u2013836. https:\/\/doi.org\/10.1002\/mds.23567","journal-title":"Mov Disord"},{"issue":"1","key":"5237_CR38","first-page":"1","volume":"7","author":"L Salerno","year":"2019","unstructured":"Salerno L, Ramat S, Solari G, Grassi G, Pallanti S (2019) Parkinson\u2019s disease with impulse control disorders: higher prevalence (frequency) of symptoms of attention deficit hyperactivity disorder. Int J Clin Psychiatry 7(1):1\u20137","journal-title":"Int J Clin Psychiatry"},{"issue":"13","key":"5237_CR39","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1038\/s41386-018-0207-5","volume":"43","author":"K Curtin","year":"2018","unstructured":"Curtin K, Fleckenstein AE, Keeshin BR, Yurgelun-Todd DA, Renshaw PF, Smith KR, Hanson GR (2018) Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit\/hyperactivity disorder. Neuropsychopharmacology 43(13):2548\u20132555. https:\/\/doi.org\/10.1038\/s41386-018-0207-5","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"5237_CR40","doi-asserted-by":"publisher","first-page":"104175","DOI":"10.1371\/journal.pone.0104175","volume":"9","author":"LA Adler","year":"2014","unstructured":"Adler LA, Clemow DB, Williams DW, Durell TM (2014) Atomoxetine effects on executive function as measured by the BRIEF--a in young adults with ADHD: a randomized, double-blind, placebo-controlled study. PLoS One 9(8):104175. https:\/\/doi.org\/10.1371\/journal.pone.0104175","journal-title":"PLoS One"},{"key":"5237_CR41","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.neuroimage.2013.08.001","volume":"86","author":"YS Ding","year":"2014","unstructured":"Ding YS, Naganawa M, Gallezot JD, Nabulsi N, Lin SF, Ropchan J, Weinzimmer D, McCarthy TJ, Carson RE, Huang Y, Laruelle M (2014) Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: implications on treatment of depression and ADHD. Neuroimage 86:164\u2013171. https:\/\/doi.org\/10.1016\/j.neuroimage.2013.08.001","journal-title":"Neuroimage"},{"issue":"4","key":"5237_CR42","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/cap.2015.0137","volume":"26","author":"G Yu","year":"2016","unstructured":"Yu G, Li GF, Markowitz JS (2016) Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol 26(4):314\u2013326. https:\/\/doi.org\/10.1089\/cap.2015.0137","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"Pt 7","key":"5237_CR43","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/brain\/awu117","volume":"137","author":"AA Kehagia","year":"2014","unstructured":"Kehagia AA, Housden CR, Regenthal R, Barker RA, M\u00fcller U, Rowe J, Sahakian BJ, Robbins TW (2014) Targeting impulsivity in Parkinson\u2019s disease using atomoxetine. Brain 137(Pt 7):1986\u20131997. https:\/\/doi.org\/10.1093\/brain\/awu117","journal-title":"Brain"},{"issue":"8","key":"5237_CR44","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/npp.2016.18","volume":"41","author":"RJ Borchert","year":"2016","unstructured":"Borchert RJ, Rittman T, Passamonti L, Ye Z, Sami S, Jones SP, Nombela C, V\u00e1zquez Rodr\u00edguez P, Vatansever D, Rae CL, Hughes LE, Robbins TW, Rowe JB (2016) Atomoxetine enhances connectivity of prefrontal networks in Parkinson\u2019s disease. Neuropsychopharmacology 41(8):2171\u20132177. https:\/\/doi.org\/10.1038\/npp.2016.18 Erratum in: Neuropsychopharmacology. 2016;41(8):2188","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"5237_CR45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.biopsych.2014.01.024","volume":"77","author":"Z Ye","year":"2015","unstructured":"Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB (2015) Improving response inhibition in Parkinson\u2019s disease with atomoxetine. Biol Psychiatry 77(8):740\u2013748. https:\/\/doi.org\/10.1016\/j.biopsych.2014.01.024","journal-title":"Biol Psychiatry"},{"issue":"Pt 8","key":"5237_CR46","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1093\/brain\/aww138","volume":"139","author":"CL Rae","year":"2016","unstructured":"Rae CL, Nombela C, Rodr\u00edguez PV, Ye Z, Hughes LE, Jones PS, Ham T, Rittman T, Coyle-Gilchrist I, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB (2016) Atomoxetine restores the response inhibition network in Parkinson\u2019s disease. Brain 139(Pt 8):2235\u20132248. https:\/\/doi.org\/10.1093\/brain\/aww138","journal-title":"Brain"},{"issue":"2","key":"5237_CR47","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/mds.22307","volume":"24","author":"L Marsh","year":"2009","unstructured":"Marsh L, Biglan K, Gerstenhaber M, Williams JR (2009) Atomoxetine for the treatment of executive dysfunction in Parkinson\u2019s disease: a pilot open-label study. Mov Disord 24(2):277\u2013282. https:\/\/doi.org\/10.1002\/mds.22307","journal-title":"Mov Disord"},{"issue":"3","key":"5237_CR48","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/mdc3.12455","volume":"4","author":"VK Hinson","year":"2016","unstructured":"Hinson VK, Delambo A, Elm J, Turner T (2016) A Randomized clinical trial of atomoxetine for mild cognitive impairment in Parkinson\u2019s disease. Mov Disord Clin Pract 4(3):416\u2013423. https:\/\/doi.org\/10.1002\/mdc3.12455","journal-title":"Mov Disord Clin Pract"},{"issue":"5","key":"5237_CR49","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/WNL.0b013e3181ebdd79","volume":"75","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Nazem S, Ten Have TR, Stern MB (2010) Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 75(5):448\u2013455. https:\/\/doi.org\/10.1212\/WNL.0b013e3181ebdd79","journal-title":"Neurology"},{"key":"5237_CR50","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jpsychires.2016.09.012","volume":"83","author":"G Grassi","year":"2016","unstructured":"Grassi G, Micheli L, Di Cesare Mannelli L, Compagno E, Righi L, Ghelardini C, Pallanti S (2016) Atomoxetine for hoarding disorder: a pre-clinical and clinical investigation. J Psychiatr Res 83:240\u2013248. https:\/\/doi.org\/10.1016\/j.jpsychires.2016.09.012","journal-title":"J Psychiatr Res"},{"issue":"8","key":"5237_CR51","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/mds.23016","volume":"25","author":"SS O\u2019Sullivan","year":"2010","unstructured":"O\u2019Sullivan SS, Djamshidian A, Evans AH, Loane CM, Lees AJ, Lawrence AD (2010) Excessive hoarding in Parkinson\u2019s disease. Mov Disord 25(8):1026\u20131033. https:\/\/doi.org\/10.1002\/mds.23016","journal-title":"Mov Disord"},{"key":"5237_CR52","doi-asserted-by":"publisher","first-page":"h5203","DOI":"10.1136\/bmj.h5203","volume":"351","author":"OJ Storeb\u00f8","year":"2015","unstructured":"Storeb\u00f8 OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, Nilausen TD, Magnusson FL, Zwi M, Gillies D, Rosendal S, Groth C, Rasmussen KB, Gauci D, Kirubakaran R, Forsb\u00f8l B, Simonsen E, Gluud C (2015) Methylphenidate for attention-deficit\/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ 351:h5203. https:\/\/doi.org\/10.1136\/bmj.h5203","journal-title":"BMJ"},{"issue":"14","key":"5237_CR53","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1212\/WNL.0b013e3182143537","volume":"76","author":"AJ Espay","year":"2011","unstructured":"Espay AJ, Dwivedi AK, Payne M, Gaines L, Vaughan JE, Maddux BN, Slevin JT, Gartner M, Sahay A, Revilla FJ, Duker AP, Shukla R (2011) Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology 76(14):1256\u20131262. https:\/\/doi.org\/10.1212\/WNL.0b013e3182143537","journal-title":"Neurology"},{"issue":"7","key":"5237_CR54","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1474-4422(12)70106-0","volume":"11","author":"C Moreau","year":"2012","unstructured":"Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, Vuillaume I, Corvol JC, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Malt\u00eate D, Tranchant C, Houeto JL, Deb\u00fb B, Sablonniere B, Azulay JP, Tison F, Rascol O, Vidailhet M, Dest\u00e9e A, Bloem BR, Bordet R, Devos D, Parkgait-II study group (2012) Methylphenidate for gait hypokinesia and freezing in patients with Parkinson\u2019s disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 11(7):589\u2013596. https:\/\/doi.org\/10.1016\/S1474-4422(12)70106-0","journal-title":"Lancet Neurol"},{"issue":"3","key":"5237_CR55","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/ana.22029","volume":"68","author":"A Thomas","year":"2010","unstructured":"Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68(3):400\u2013404. https:\/\/doi.org\/10.1002\/ana.22029","journal-title":"Ann Neurol"},{"issue":"6","key":"5237_CR56","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ana.22164","volume":"68","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68(6):963\u2013968. https:\/\/doi.org\/10.1002\/ana.22164","journal-title":"Ann Neurol"},{"issue":"3","key":"5237_CR57","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/s0306-4522(99)00037-8","volume":"92","author":"M Riekkinen","year":"1999","unstructured":"Riekkinen M, J\u00e4k\u00e4l\u00e4 P, Kejonen K, Riekkinen P (1999) Jr. The alpha2 agonist, clonidine, improves spatial working performance in Parkinson\u2019s disease. Neuroscience 92(3):983\u2013989. https:\/\/doi.org\/10.1016\/s0306-4522(99)00037-8","journal-title":"Neuroscience"},{"issue":"6","key":"5237_CR58","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/mds.27340","volume":"33","author":"A Antonini","year":"2018","unstructured":"Antonini A, Moro E, Godeiro C, Reichmann H (2018) Medical and surgical management of advanced Parkinson\u2019s disease. Mov Disord 33(6):900\u2013908. https:\/\/doi.org\/10.1002\/mds.27340","journal-title":"Mov Disord"},{"issue":"4","key":"5237_CR59","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41582-019-0145-9","volume":"15","author":"P Limousin","year":"2019","unstructured":"Limousin P, Foltynie T (2019) Long-term outcomes of deep brain stimulation in Parkinson disease. Nat Rev Neurol 15(4):234\u2013242. https:\/\/doi.org\/10.1038\/s41582-019-0145-9","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"5237_CR60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1176\/jnp.23.1.jnp56","volume":"23","author":"LB Zahodne","year":"2011","unstructured":"Zahodne LB, Susatia F, Bowers D, Ong TL, Jacobson CE 4th, Okun MS, Rodriguez RL, Malaty IA, Foote KD, Fernandez HH (2011) Binge eating in Parkinson\u2019s disease: prevalence, correlates and the contribution of deep brain stimulation. J Neuropsychiatr Clin Neurosci 23(1):56\u201362. https:\/\/doi.org\/10.1176\/jnp.23.1.jnp56","journal-title":"J Neuropsychiatr Clin Neurosci"},{"issue":"5","key":"5237_CR61","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/jnnp.2006.102061","volume":"78","author":"HM Smeding","year":"2007","unstructured":"Smeding HM, Goudriaan AE, Foncke EM, Schuurman PR, Speelman JD, Schmand B (2007) Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 78(5):517\u2013519. https:\/\/doi.org\/10.1136\/jnnp.2006.102061","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"20","key":"5237_CR62","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa035275","volume":"349","author":"P Krack","year":"2003","unstructured":"Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, Pollak P (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson\u2019s disease. N Engl J Med 349(20):1925\u20131934. https:\/\/doi.org\/10.1056\/NEJMoa035275","journal-title":"N Engl J Med"},{"issue":"6","key":"5237_CR63","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1136\/jnnp.2002.009803","volume":"75","author":"A Funkiewiez","year":"2004","unstructured":"Funkiewiez A, Ardouin C, Caputo E, Krack P, Fraix V, Klinger H, Chabardes S, Foote K, Benabid AL, Pollak P (2004) Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 75(6):834\u2013839. https:\/\/doi.org\/10.1136\/jnnp.2002.009803","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"5237_CR64","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1136\/jnnp.2005.063206","volume":"76","author":"WM Sch\u00fcpbach","year":"2005","unstructured":"Sch\u00fcpbach WM, Chastan N, Welter ML, Houeto JL, Mesnage V, Bonnet AM, Czernecki V, Malt\u00eate D, Hartmann A, Mallet L, Pidoux B, Dormont D, Navarro S, Cornu P, Mallet A, Agid Y (2005) Stimulation of the subthalamic nucleus in Parkinson\u2019s disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 76(12):1640\u20131644. https:\/\/doi.org\/10.1136\/jnnp.2005.063206","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"5237_CR65","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.parkreldis.2004.01.007","volume":"10","author":"M Sensi","year":"2004","unstructured":"Sensi M, Eleopra R, Cavallo MA, Sette E, Milani P, Quatrale R, Capone JG, Tugnoli V, Tola MR, Granieri E, Data PG (2004) Explosive-aggressive behavior related to bilateral subthalamic stimulation. Parkinsonism Relat Disord 10(4):247\u2013251. https:\/\/doi.org\/10.1016\/j.parkreldis.2004.01.007","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"5237_CR66","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/mds.10265","volume":"17","author":"LM Romito","year":"2002","unstructured":"Romito LM, Raja M, Daniele A, Contarino MF, Bentivoglio AR, Barbier A, Scerrati M, Albanese A (2002) Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson\u2019s disease. Mov Disord 17(6):1371\u20131374. https:\/\/doi.org\/10.1002\/mds.10265","journal-title":"Mov Disord"},{"key":"5237_CR67","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jns.2017.01.019","volume":"374","author":"C Kasemsuk","year":"2017","unstructured":"Kasemsuk C, Oyama G, Hattori N (2017) Management of impulse control disorders with deep brain stimulation: a double-edged sword. J Neurol Sci 374:63\u201368. https:\/\/doi.org\/10.1016\/j.jns.2017.01.019","journal-title":"J Neurol Sci"},{"issue":"1","key":"5237_CR68","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00415-016-8314-x","volume":"264","author":"A Merola","year":"2017","unstructured":"Merola A, Romagnolo A, Rizzi L, Rizzone MG, Zibetti M, Lanotte M, Mandybur G, Duker AP, Espay AJ, Lopiano L (2017) Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease. J Neurol 264(1):40\u201348. https:\/\/doi.org\/10.1007\/s00415-016-8314-x","journal-title":"J Neurol"},{"issue":"3","key":"5237_CR69","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/sj.npp.1301432","volume":"33","author":"S Lardeux","year":"2008","unstructured":"Lardeux S, Baunez C (2008) Alcohol preference influences the subthalamic nucleus control on motivation for alcohol in rats. Neuropsychopharmacology 33(3):634\u2013642. https:\/\/doi.org\/10.1038\/sj.npp.1301432","journal-title":"Neuropsychopharmacology"},{"key":"5237_CR70","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3389\/fnins.2018.00385","volume":"12","author":"RS Eisinger","year":"2018","unstructured":"Eisinger RS, Urdaneta ME, Foote KD, Okun MS, Gunduz A (2018) Non-motor characterization of the basal ganglia: evidence from human and non-human primate electrophysiology. Front Neurosci 12:385. https:\/\/doi.org\/10.3389\/fnins.2018.00385","journal-title":"Front Neurosci"},{"key":"5237_CR71","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.neuropsychologia.2018.02.016","volume":"117","author":"F Fluch\u00e8re","year":"2018","unstructured":"Fluch\u00e8re F, Burle B, Vidal F, van den Wildenberg W, Witjas T, Eusebio A, Azulay JP, Hasbroucq T (2018) Subthalamic nucleus stimulation, dopaminergic treatment and impulsivity in Parkinson\u2019s disease. Neuropsychologia 117:167\u2013177. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2018.02.016","journal-title":"Neuropsychologia"},{"issue":"7","key":"5237_CR72","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00221-016-4577-9","volume":"234","author":"I Pote","year":"2016","unstructured":"Pote I, Torkamani M, Kefalopoulou ZM, Zrinzo L, Limousin-Dowsey P, Foltynie T, Speekenbrink M, Jahanshahi M (2016) Subthalamic nucleus deep brain stimulation induces impulsive action when patients with Parkinson\u2019s disease act under speed pressure. Exp Brain Res 234(7):1837\u20131848. https:\/\/doi.org\/10.1007\/s00221-016-4577-9","journal-title":"Exp Brain Res"},{"key":"5237_CR73","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neuropsychologia.2017.02.016","volume":"99","author":"NC van Wouwe","year":"2017","unstructured":"van Wouwe NC, Pallavaram S, Phibbs FT, Martinez-Ramirez D, Neimat JS, Dawant BM, D\u2019Haese PF, Kanoff KE, van den Wildenberg WPM, Okun MS, Wylie SA (2017) Focused stimulation of dorsal subthalamic nucleus improves reactive inhibitory control of action impulses. Neuropsychologia 99:37\u201347. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2017.02.016","journal-title":"Neuropsychologia"},{"issue":"8","key":"5237_CR74","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1136\/jnnp-2012-302387","volume":"84","author":"A Eusebio","year":"2013","unstructured":"Eusebio A, Witjas T, Cohen J, Fluch\u00e8re F, Jouve E, R\u00e9gis J, Azulay JP (2013) Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 84(8):868\u2013874. https:\/\/doi.org\/10.1136\/jnnp-2012-302387","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"5237_CR75","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/jnnp-2017-316373","volume":"89","author":"M Abbes","year":"2018","unstructured":"Abbes M, Lhomm\u00e9e E, Thobois S, Klinger H, Schmitt E, Bichon A, Castrioto A, Xie J, Fraix V, Kistner A, P\u00e9lissier P, Seigneuret \u00c9, Chabard\u00e8s S, Mertens P, Broussolle E, Moro E, Krack P (2018) Subthalamic stimulation and neuropsychiatric symptoms in Parkinson\u2019s disease: results from a long-term follow-up cohort study. J Neurol Neurosurg Psychiatry 89(8):836\u2013843. https:\/\/doi.org\/10.1136\/jnnp-2017-316373","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Pt 5","key":"5237_CR76","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/brain\/aws078","volume":"135","author":"E Lhomm\u00e9e","year":"2012","unstructured":"Lhomm\u00e9e E, Klinger H, Thobois S, Schmitt E, Ardouin C, Bichon A, Kistner A, Fraix V, Xie J, Aya Kombo M, Chabard\u00e8s S, Seigneuret E, Benabid AL, Mertens P, Polo G, Carnicella S, Quesada JL, Bosson JL, Broussolle E, Pollak P, Krack P (2012) Subthalamic stimulation in Parkinson\u2019s disease: restoring the balance of motivated behaviours. Brain 135(Pt 5):1463\u20131477. https:\/\/doi.org\/10.1093\/brain\/aws078","journal-title":"Brain"},{"issue":"11","key":"5237_CR77","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/mds.21098","volume":"21","author":"C Ardouin","year":"2006","unstructured":"Ardouin C, Voon V, Worbe Y, Abouazar N, Czernecki V, Hosseini H, Pelissolo A, Moro E, Lhomm\u00e9e E, Lang AE, Agid Y, Benabid AL, Pollak P, Mallet L, Krack P (2006) Pathological gambling in Parkinson\u2019s disease improves on chronic subthalamic nucleus stimulation. Mov Disord 21(11):1941\u20131946. https:\/\/doi.org\/10.1002\/mds.21098","journal-title":"Mov Disord"},{"issue":"3","key":"5237_CR78","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/WNN.0b013e318185e6e2","volume":"21","author":"D Knobel","year":"2008","unstructured":"Knobel D, Aybek S, Pollo C, Vingerhoets FJ, Berney A (2008) Rapid resolution of dopamine dysregulation syndrome (DDS) after subthalamic DBS for Parkinson disease (PD): a case report. Cogn Behav Neurol 21(3):187\u2013189. https:\/\/doi.org\/10.1097\/WNN.0b013e318185e6e2","journal-title":"Cogn Behav Neurol"},{"issue":"6","key":"5237_CR79","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.parkreldis.2006.07.011","volume":"13","author":"F Bandini","year":"2007","unstructured":"Bandini F, Primavera A, Pizzorno M, Cocito L (2007) Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson\u2019s disease. Parkinsonism Relat Disord 13(6):369\u2013371. https:\/\/doi.org\/10.1016\/j.parkreldis.2006.07.011","journal-title":"Parkinsonism Relat Disord"},{"key":"5237_CR80","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.08.006","volume":"44","author":"PJ Rossi","year":"2017","unstructured":"Rossi PJ, De Jesus S, Hess CW, Martinez-Ramirez D, Foote KD, Gunduz A, Okun MS (2017) Measures of impulsivity in Parkinson\u2019s disease decrease after DBS in the setting of stable dopamine therapy. Parkinsonism Relat Disord 44:13\u201317. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.08.006","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"5237_CR81","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1474-4422(18)30035-8","volume":"17","author":"E Lhomm\u00e9e","year":"2018","unstructured":"Lhomm\u00e9e E, Wojtecki L, Czernecki V, Witt K, Maier F, Tonder L, Timmermann L, H\u00e4lbig TD, Pineau F, Durif F, Witjas T, Pinsker M, Mehdorn M, Sixel-D\u00f6ring F, Kupsch A, Kr\u00fcger R, Elben S, Chabard\u00e8s S, Thobois S, Brefel-Courbon C, Ory-Magne F, Regis JM, Malt\u00eate D, Sauvaget A, Rau J, Schnitzler A, Sch\u00fcpbach M, Schade-Brittinger C, Deuschl G, Houeto JL, Krack P, EARLYSTIM study group (2018) Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson\u2019s disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol 17(3):223\u2013231. https:\/\/doi.org\/10.1016\/S1474-4422(18)30035-8","journal-title":"Lancet Neurol"},{"key":"5237_CR82","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/bs.irn.2017.05.009","volume":"134","author":"I Rektorov\u00e1","year":"2017","unstructured":"Rektorov\u00e1 I, Anderkov\u00e1 L (2017) Noninvasive brain stimulation and implications for nonmotor symptoms in Parkinson\u2019s disease. Int Rev Neurobiol 134:1091\u20131110. https:\/\/doi.org\/10.1016\/bs.irn.2017.05.009","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"5237_CR83","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.clinph.2016.10.087","volume":"128","author":"JP Lefaucheur","year":"2017","unstructured":"Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, Cotelli M, De Ridder D, Ferrucci R, Langguth B, Marangolo P, Mylius V, Nitsche MA, Padberg F, Palm U, Poulet E, Priori A, Rossi S, Schecklmann M, Vanneste S, Ziemann U, Garcia-Larrea L, Paulus W (2017) Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol 128(1):56\u201392. https:\/\/doi.org\/10.1016\/j.clinph.2016.10.087","journal-title":"Clin Neurophysiol"},{"issue":"1","key":"5237_CR84","doi-asserted-by":"publisher","first-page":"14840","DOI":"10.1038\/s41598-017-13260-z","volume":"7","author":"AM Goodwill","year":"2017","unstructured":"Goodwill AM, Lum JAG, Hendy AM, Muthalib M, Johnson L, Albein-Urios N, Teo WP (2017) Using non-invasive transcranial stimulation to improve motor and cognitive function in Parkinson\u2019s disease: a systematic review and meta-analysis. Sci Rep 7(1):14840. https:\/\/doi.org\/10.1038\/s41598-017-13260-z","journal-title":"Sci Rep"},{"key":"5237_CR85","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/bs.irn.2017.05.031","volume":"133","author":"R Biundo","year":"2017","unstructured":"Biundo R, Fiorenzato E, Antonini A (2017) Nonmotor symptoms and natural history of Parkinson\u2019s disease: evidence from cognitive dysfunction and role of noninvasive interventions. Int Rev Neurobiol 133:389\u2013415. https:\/\/doi.org\/10.1016\/bs.irn.2017.05.031","journal-title":"Int Rev Neurobiol"},{"issue":"2-3","key":"5237_CR86","doi-asserted-by":"publisher","first-page":"89","DOI":"10.12871\/00039829201925","volume":"157","author":"G Orr\u00f9","year":"2019","unstructured":"Orr\u00f9 G, Baroni M, Cesari V, Conversano C, Hitchcott PK, Gemignani A (2019) The effect of single and repeated tDCS sessions on motor symptoms in Parkinson\u2019s disease: a systematic review. Arch Ital Biol 157(2-3):89\u2013101. https:\/\/doi.org\/10.12871\/00039829201925","journal-title":"Arch Ital Biol"},{"key":"5237_CR87","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.parkreldis.2019.10.009","volume":"68","author":"TM Mi","year":"2019","unstructured":"Mi TM, Garg S, Ba F, Liu AP, Wu T, Gao LL, Dan XJ, Chan P, McKeown MJ (2019) High-frequency rTMS over the supplementary motor area improves freezing of gait in Parkinson\u2019s disease: a randomized controlled trial. Parkinsonism Relat Disord 68:85\u201390. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.10.009","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"5237_CR88","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3988\/jcn.2018.14.3.320","volume":"14","author":"SJ Kim","year":"2018","unstructured":"Kim SJ, Paeng SH, Kang SY (2018) Stimulation in supplementary motor area versus motor cortex for freezing of gait in Parkinson\u2019s disease. J Clin Neurol 14(3):320\u2013326. https:\/\/doi.org\/10.3988\/jcn.2018.14.3.320","journal-title":"J Clin Neurol"},{"key":"5237_CR89","doi-asserted-by":"publisher","first-page":"134837","DOI":"10.1016\/j.neulet.2020.134837","volume":"724","author":"L Hano\u011flu","year":"2020","unstructured":"Hano\u011flu L, Saricaoglu M, Toprak G, Y\u0131lmaz NH, Yulu\u011f B (2020) Preliminary findings on the role of high-frequency (5 Hz) rTMS stimulation on M1 and pre-SMA regions in Parkinson\u2019s disease. Neurosci Lett 724:134837. https:\/\/doi.org\/10.1016\/j.neulet.2020.134837","journal-title":"Neurosci Lett"},{"key":"5237_CR90","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.parkreldis.2019.07.006","volume":"66","author":"J Trung","year":"2019","unstructured":"Trung J, Hanganu A, Jobert S, Degroot C, Mejia-Constain B, Kibreab M, Bruneau MA, Lafontaine AL, Strafella A, Monchi O (2019) Transcranial magnetic stimulation improves cognition over time in Parkinson\u2019s disease. Parkinsonism Relat Disord 66:3\u20138. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.07.006","journal-title":"Parkinsonism Relat Disord"},{"key":"5237_CR91","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3389\/fpsyt.2018.00769","volume":"9","author":"L Zhou","year":"2019","unstructured":"Zhou L, Guo Z, Xing G, Peng H, Cai M, Chen H, McClure MA, He L, Xiong L, He B, Du F, Mu Q (2019) Antidepressant effects of repetitive transcranial magnetic stimulation over prefrontal cortex of Parkinson\u2019s Disease Patients With Depression: A Meta-Analysis. Front Psych 9:769. https:\/\/doi.org\/10.3389\/fpsyt.2018.00769","journal-title":"Front Psych"},{"issue":"5","key":"5237_CR92","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1017\/S1092852918000846","volume":"23","author":"G Grassi","year":"2018","unstructured":"Grassi G, Figee M, Ooms P, Righi L, Nakamae T, Pallanti S, Schuurman R, Denys D (2018) Impulsivity and decision-making in obsessive-compulsive disorder after effective deep brain stimulation or treatment as usual. CNS Spectr 23(5):333\u2013339. https:\/\/doi.org\/10.1017\/S1092852918000846","journal-title":"CNS Spectr"},{"issue":"6","key":"5237_CR93","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3928\/00485713-20150602-07","volume":"45","author":"S Pallanti","year":"2015","unstructured":"Pallanti S, Marras A, Grassi G (2015) Outcomes with neuromodulation in obsessive-compulsive disorder. Psychiatr Ann 45(6):316\u2013320","journal-title":"Psychiatr Ann"},{"key":"5237_CR94","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fpsyt.2020.00158","volume":"11","author":"G Madeo","year":"2020","unstructured":"Madeo G, Terraneo A, Cardullo S, G\u00f3mez P\u00e9rez LJ, Cellini N, Sarlo M, Bonci A, Gallimberti L (2020) Long-term outcome of repetitive transcranial magnetic stimulation in a large cohort of patients with cocaine-use disorder: an observational study. Front Psychiatry 11:158. https:\/\/doi.org\/10.3389\/fpsyt.2020.00158","journal-title":"Front Psychiatry"},{"key":"5237_CR95","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12984-018-0457-9","volume":"15","author":"B Dobbs","year":"2018","unstructured":"Dobbs B, Pawlak N, Biagioni M, Agarwal S, Shaw M, Pilloni G, Bikson M, Datta A, Charvet L (2018) Generalizing remotely supervised transcranial direct current stimulation (tDCS): feasibility and benefit in Parkinson\u2019s disease. J Neuroeng Rehabil 15:114. https:\/\/doi.org\/10.1186\/s12984-018-0457-9","journal-title":"J Neuroeng Rehabil"},{"key":"5237_CR96","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s12311-015-0737-x","volume":"15","author":"R Ferrucci","year":"2016","unstructured":"Ferrucci R, Cortese F, Bianchi M, Pittera D, Turrone R, Bocci T, Borroni B, Vergari M, Cogiamanian F, Ardolino G, Di Fonzo A, Padovani A, Priori A (2016) Cerebellar and motor cortical transcranial stimulation decrease levodopa-induced dyskinesias in Parkinson\u2019s disease. Cerebellum 15:43\u201347. https:\/\/doi.org\/10.1007\/s12311-015-0737-x","journal-title":"Cerebellum"},{"key":"5237_CR97","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3389\/fnhum.2013.00928","volume":"7","author":"V Krause","year":"2014","unstructured":"Krause V, Wach C, S\u00fcdmeyer M, Ferrea S, Schnitzler A, Pollok B (2014) Cortico-muscular coupling and motor performance are modulated by 20 Hz transcranial alternating current stimulation (tACS) in Parkinson\u2019s disease. Front Hum Neurosci 7:928. https:\/\/doi.org\/10.3389\/fnhum.2013.00928","journal-title":"Front Hum Neurosci"},{"key":"5237_CR98","doi-asserted-by":"publisher","first-page":"101768","DOI":"10.1016\/j.nicl.2019.101768","volume":"22","author":"A Del Felice","year":"2019","unstructured":"Del Felice A, Castiglia L, Formaggio E, Cattelan M, Scarpa B, Manganotti P, Tenconi E, Masiero S (2019) Personalized transcranial alternating current stimulation (tACS) and physical therapy to treat motor and cognitive symptoms in Parkinson\u2019s disease: a randomized cross-over trial. Neuroimage Clin 22:101768. https:\/\/doi.org\/10.1016\/j.nicl.2019.101768","journal-title":"Neuroimage Clin"},{"issue":"6","key":"5237_CR99","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.brs.2018.07.046","volume":"11","author":"R Manenti","year":"2018","unstructured":"Manenti R, Cotelli MS, Cobelli C, Gobbi E, Brambilla M, Rusich D, Alberici A, Padovani A, Borroni B, Cotelli M (2018) Transcranial direct current stimulation combined with cognitive training for the treatment of Parkinson disease: a randomized, placebo-controlled study. Brain Stimul 11(6):1251\u20131262. https:\/\/doi.org\/10.1016\/j.brs.2018.07.046","journal-title":"Brain Stimul"},{"key":"5237_CR100","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neulet.2014.08.043","volume":"582","author":"D Doruk","year":"2014","unstructured":"Doruk D, Gray Z, Bravo GL, Pascual-Leone A, Fregni F (2014) Effects of tDCS on executive function in Parkinson\u2019s disease. Neurosci Lett 582:27\u201331. https:\/\/doi.org\/10.1016\/j.neulet.2014.08.043","journal-title":"Neurosci Lett"},{"issue":"Suppl 1","key":"5237_CR101","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.parkreldis.2017.07.030","volume":"46","author":"G Cossu","year":"2018","unstructured":"Cossu G, Rinaldi R, Colosimo C (2018) The rise and fall of impulse control behavior disorders. Parkinsonism Relat Disord 46(Suppl 1):S24\u2013S29. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.07.030","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05237-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05237-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05237-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T08:19:25Z","timestamp":1625645965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05237-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":101,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["5237"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05237-8","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]},"assertion":[{"value":"12 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the authors approved the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}}]}}